Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TruScreen Group Limited Share Issue/Capital Change 2018

Sep 25, 2018

66285_rns_2018-09-25_e2845055-a813-4332-8098-5ff5d02347af.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

25 September 2018

Company Announcement

TruScreen Share Placement

ISSUE OF SECURITIES BY

TRUSCREEN LIMITED (TRU)

TruScreen Limited advises that it has issued new shares as follows: Class of Security: Ordinary Shares (TRU) Number issued: 100,000 ordinary shares at NZD 10 cents each fully paid Payment: Cash on subscription Percentage of total Class of Securities issued: 0.05% (of the total number of ordinary shares on issue post completion of the issue) Reason for the issue: Exercise of options awarded to Mr Yaniv Gal by Directors Resolution on 8 October, 2014: Authority of issue : Director’s Resolution and Certificate Terms of issue: The new shares are credited as fully paid, and rank in all respects equally with the shares already on issue. Total number of securities of the Class in existence after the issue: 209,445,477 Date of issue: 25 September 2018

TRUSCREEN LIMITED

Martin Dillon

Chief Executive Officer

-ENDS-

For more information visit www.truscreen.com

or contact

Martin Dillon,

TruScreen Chief Executive Officer, email: [email protected]

About TruScreen:

TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.

==> picture [297 x 186] intentionally omitted <==